Sun unit resolves antitrust lawsuit for $485m

Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Court denies Sun Pharma’s bid to avoid trial

25 November 2021 Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.

Generics

Lupin and Sun settle Bromsite patent suit after ruling

10 February 2022 Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September.

More on this story

Big Pharma

Court denies Sun Pharma’s bid to avoid trial

25 November 2021 Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.

Generics

Lupin and Sun settle Bromsite patent suit after ruling

More on this story

Big Pharma

Court denies Sun Pharma’s bid to avoid trial

25 November 2021 Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.

Generics

Lupin and Sun settle Bromsite patent suit after ruling